Latest News

Could the Omicron surge hasten the transition from pandemic to endemic?


 

A shorter, more intense surge?

The United Kingdom’s experience with COVID-19 has often served as a bellwether of what is likely to happen in the U.S. If that is the case with the Omicron surge, the peak should last about 4 weeks, Dr. Mylonakis said.

In other words, the accelerated spread of Omicron could mean this surge passes more quickly than Delta.

Furthermore, some evidence suggests neutralizing antibodies produced by Omicron infection remain effective against the Delta variant – thereby reducing the risk of Delta reinfections over time.

The ability to neutralize the Delta variant increased more than fourfold after a median 14 days, according to data from a preprint study posted Dec. 27 on MedRxiv.

At the same time, neutralization of the Omicron variant increased 14-fold as participants mounted an antibody response. The study was conducted in vaccinated and unvaccinated people infected by Omicron in South Africa shortly after symptoms started. It has yet to be peer reviewed.

Eric Topol, MD, editor-in-chief of Medscape, described the results as “especially good news” in a tweet.

The current surge could also mean enhanced protection in the future.

“As we look at getting to the other side of this Omicron wave, we will end up with more immunity,” Dr. Madad said. “And with more immunity means we’ll be better guarded against the next emerging variant.”

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

COVID-19–positive or exposed? What to do next
MDedge Hematology and Oncology
Why patients should ditch cloth masks
MDedge Hematology and Oncology
Travel/school disruptions as COVID-19 cases grow in 2022
MDedge Hematology and Oncology
FDA backs Pfizer booster for 12- to 15-year-olds
MDedge Hematology and Oncology
COVID-19 outbreak hits research station in Antarctica
MDedge Hematology and Oncology
New CDC COVID-19 isolation guidelines still up for debate among experts
MDedge Hematology and Oncology
CDC defends new COVID guidance as doctors raise concerns
MDedge Hematology and Oncology
Who needs self-driving cars when we’ve got goldfish?
MDedge Hematology and Oncology
CDC panel recommends Pfizer COVID-19 boosters for ages 12-15
MDedge Hematology and Oncology
As Omicron surges, hospital beds fill, but ICUs less affected
MDedge Hematology and Oncology